Why the study?
What are the predictors and outcomes of the no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention?
What are the predictors and outcomes of the no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention?
The development of the no-reflow phenomenon during primary PCI for STEMI is a strong predictor of high in-hospital and long-term morbidity and mortality.
Answers are grounded in this paper and cite their sources.
No-reflow signals very high short- and long-term risk in STEMI PCI; hypothesis-generating for mitigation strategies, pending prospective trials.
The no-reflow predictors that were identified in this study might be useful in the determination of the patients who could benefit from aggressive pharmaco-invasive therapy. Development of no-reflow is associated with both in-hospital and long-term very high morbidity and mortality rates.
No takes yet. Share an insight, caveat, or question.
Taşar et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: